The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial decrease in bo